Belite Bio (NASDAQ:BLTE - Get Free Report) had its price target upped by equities researchers at Maxim Group from $60.00 to $110.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Maxim Group's target price would indicate a potential upside of 31.75% from the company's current price.
BLTE has been the subject of a number of other research reports. HC Wainwright increased their price target on Belite Bio from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Wednesday. Benchmark reaffirmed a "buy" rating and set a $57.00 target price on shares of Belite Bio in a research note on Tuesday, August 13th.
Read Our Latest Analysis on Belite Bio
Belite Bio Stock Down 0.2 %
Shares of NASDAQ BLTE traded down $0.17 during mid-day trading on Friday, hitting $83.49. 37,378 shares of the company traded hands, compared to its average volume of 54,539. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of -75.22 and a beta of -1.60. The business has a 50 day moving average of $58.53 and a two-hundred day moving average of $51.23. Belite Bio has a 1 year low of $31.00 and a 1 year high of $86.53.
Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.02. During the same quarter last year, the business posted ($0.40) earnings per share. As a group, research analysts anticipate that Belite Bio will post -1.19 EPS for the current year.
Institutional Investors Weigh In On Belite Bio
A hedge fund recently bought a new stake in Belite Bio stock. Armistice Capital LLC bought a new stake in shares of Belite Bio, Inc (NASDAQ:BLTE - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 148,000 shares of the company's stock, valued at approximately $6,761,000. Armistice Capital LLC owned approximately 0.50% of Belite Bio at the end of the most recent quarter. 0.53% of the stock is owned by hedge funds and other institutional investors.
Belite Bio Company Profile
(
Get Free Report)
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Belite Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.
While Belite Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
